a provider of immunotherapy products for the treatment of cancer and infectious diseases
Industry Biotechnology
A.I.dvisor tells us that CVM and IDYA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVM and IDYA's prices will move in lockstep.
Ticker / NAME | Correlation To CVM | 1D Price Change % | ||
---|---|---|---|---|
CVM | 100% | N/A | ||
IDYA - CVM | 31% Poorly correlated | -3.52% | ||
EYPT - CVM | 30% Poorly correlated | -8.88% | ||
ATHE - CVM | 28% Poorly correlated | -7.38% | ||
VTGN - CVM | 26% Poorly correlated | -3.72% | ||
STOK - CVM | 25% Poorly correlated | +3.30% | ||
More |
Ticker / NAME | Correlation To CVM | 1D Price Change % |
---|---|---|
CVM | 100% | N/A |
drugs theme (265 stocks) | 25% Poorly correlated | +5.37% |
biotechnology theme (248 stocks) | 24% Poorly correlated | +5.56% |
cancer theme (87 stocks) | 22% Poorly correlated | +0.89% |
generic products theme (74 stocks) | 21% Poorly correlated | +1.09% |
diseases theme (42 stocks) | 16% Poorly correlated | +1.03% |
More |